Sight Sciences

Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. It also develops pharmaceuticals, drug delivery systems, and diagnostics for the treatment of ophthalmic conditions. The firm's products include viscosurgical system and trabeculotomy instruments. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sight Sciences reports stellar Q4 earnings, eyes sustainable growth

Sight Sciences delivered strong revenue growth in Q4 2022, driven by successful product offerings and market expansion efforts. While facing increased operating expenses and margin challenges, the company remains optimistic about achieving cash flow breakeven by 2025 and sustaining growth through innovative technologies and market strategies.

Sight Sciences excels in Q1 earnings, eyes growth opportunities

Sight Sciences' Q1 2023 performance reflects strong revenue growth, effective cost management, and a clear path towards achieving financial targets.
The company's leadership reinforcement, strategic focus on cash flow, and discussions on market trends position it well for future success.
While facing challenges in reimbursement changes and operational efficiency, Sight Sciences is poised to leverage opportunities for innovation and growth.

Sight Sciences excels in Q2 with record revenue and clinical validation

Sight Sciences demonstrated strong financial performance, highlighted by revenue growth and operational improvements. While facing challenges related to potential impacts on product sales and reimbursement discussions, the company remains optimistic about the growth prospects of its innovative technologies and reaffirmed its annual revenue guidance.

Sight Sciences reports Q3 revenue growth amidst operational improvements

Sight Sciences delivered solid financial performance in Q3, with revenue growth, margin improvement, and cost-saving measures
While facing challenges related to market access and revenue uncertainties, the company's strengths in innovation and efficiency position it well for future growth
Strategic opportunities in product development, market expansion, and operational optimization can drive sustained success and value creation for stakeholders

Sight Sciences posts successful Q4 results amidst revenue challenges

Sight Sciences reported strong financial performance in Q4 2023, with revenue growth, improved margins, and reduced expenses.
The company faces challenges in revenue decline for Q4, optimizing commercial strategies, and navigating reimbursement landscapes.
Opportunities lie in market expansion, revenue growth, reimbursement wins, and shifting treatment paradigms towards minimally invasive interventions.
Overall, Sight Sciences is well-positioned with a focus on innovation, clinical efficacy, and commercial strategies for 2024 opportunities.

Sight Sciences reports record Q1 revenue and eyes sustained growth

Sight Sciences posted strong financials with record revenue and improved cash usage.
Focused on driving growth in Surgical Glaucoma and addressing challenges in Dry Eye market.
Opportunities lie in market expansion, technology adoption, and sustained growth.
Company optimistic about achieving double-digit growth in the coming quarters.

Sight Sciences reports strong Q2 results, eyes growth opportunities ahead

Sight Sciences demonstrated robust financial and operational performance in Q2 2024, driven by revenue growth and improved cash management.
Strategic initiatives in surgeon training, product differentiation, and pricing reflect the company's focus on market expansion and value realization.
While facing challenges in revenue outlook and market dynamics, Sight Sciences remains poised to capitalize on growth opportunities in both Surgical Glaucoma and Dry Eye segments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

Sight Sciences, Inc. (NASDAQ:SGHT ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Chief Executive Officer Jesse Selnick - Chief Financial Officer Conference Call Participants Cecilia Furlong - Morgan Stanley David Saxon - Needham & company Thomas Stephan - Stifel Financial Corp. Craig Bijou - Bank of America Securities, Inc. Operator Good day, and thank you for standing by. Welcome to the Sight Sciences Third Quarter 2022 Earnings Results Conference Call.

Sight Sciences, Inc. (SGHT) Q3 2022 Earnings Call Transcript

Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 2.13% and 5.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates

MENLO PARK, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today reported financial results for the third quarter ended September 30, 2022.

Sight Sciences Reports Third Quarter 2022 Financial Results

Sight Sciences, Inc. (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Should You Buy?

MENLO PARK, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced it will report financial results for the third quarter ended September 30, 2022, after the market close on Thursday, November 10, 2022. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022

MENLO PARK, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives today announced Clinical Ophthalmology has published data from a subgroup analysis of the OLYMPIA trial, which showed a single treatment with the TearCare System led to superior symptoms relief across the following primary symptoms endpoints (Ocular Surface Disease Index – OSDI, Symptom Assessment in Dry Eye – SANDE, Eye Dryness - ED) compared to a LipiFlow application in patients with more severe forms of DED due to meibomian gland dysfunction (MGD).1

Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)

First-time Preview of the Ergo-Series of the OMNI® Surgical System and Exhibition of the New SION™ Surgical Instrument to be Showcased at AAO Booth 4843 First-time Preview of the Ergo-Series of the OMNI® Surgical System and Exhibition of the New SION™ Surgical Instrument to be Showcased at AAO Booth 4843

Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the OMNI Surgical System as a Standalone (Non-Combination Cataract) Glaucoma Treatment at American Academy of Ophthalmology Annual Meeting

Compendium of clinical presentations includes studies with up to 3.5 years of patient follow-up and over 400 eyes treated in 31 centers in both combination cataract and standalone use Compendium of clinical presentations includes studies with up to 3.5 years of patient follow-up and over 400 eyes treated in 31 centers in both combination cataract and standalone use

Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting

MENLO PARK, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced the completion of enrollment in the SAHARA Trial, a first of its kind outcomes study designed to evaluate whether an interventional dry eye procedure with the TearCare System is superior in alleviating the signs and symptoms of dry eye disease compared to 6-months of twice daily Restasis® dry eye eyedrops (cyclosporine ophthalmic emulsion, 0.05%). Primary endpoints measured by a masked assessor at 6 months include changes from baseline of Tear Breakup Time (sign) and Ocular Surface Disease Index Score (symptom). Results from the 310-patient, 1:1 randomized SAHARA trial are expected to be available in late Q2 2023.

Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare® System vs Restasis®

MENLO PARK, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients' lives, today announced plans to present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to present on Wednesday, August 31, 2022, at 2:30pm ET.

Sight Sciences to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

Featuring bladeless technology, SION is designed to facilitate a smooth, gentle goniotomy procedure Featuring bladeless technology, SION is designed to facilitate a smooth, gentle goniotomy procedure

Sight Sciences Introduces the SION™ Surgical Instrument – The First Bladeless Device Used in Goniotomy

Sight Sciences went public in July 2021, raising $240 million in an IPO. The firm develops and sells various surgical devices for treatment of glaucoma and dry eye conditions.

Sight Sciences Grows Portfolio Amid Reimbursement Pressure

Three-year, standalone (not combined with cataract surgery) data shows the non-implantable minimally invasive glaucoma surgery effectively reduces intraocular pressure and reduces need for IOP-lowering medications in open-angle glaucoma patients Three-year, standalone (not combined with cataract surgery) data shows the non-implantable minimally invasive glaucoma surgery effectively reduces intraocular pressure and reduces need for IOP-lowering medications in open-angle glaucoma patients

Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma

Sight Sciences, Inc. (NASDAQ:SGHT ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Officer Jesse Selnick - Chief Financial Officer Conference Call Participants Cecilia Furlong - Morgan Stanley Andrew Brackmann - William Blair Matthew O'Brien - Piper Sandler Joanne Wuensch - Citibank Tom Stephan - Stifel Operator Hello and welcome to the Sight Sciences' Second Quarter 2022 Earnings Results Conference Call. All lines have been placed on mute to prevent any background noise.

Sight Sciences, Inc. (SGHT) CEO Paul Badawi on Q2 2022 Results - Earnings Call Transcript

Sight Sciences (SGHT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Sight Sciences (SGHT) Might Surprise This Earnings Season

The consensus price target hints at a 121.5% upside potential for Sight Sciences, Inc. (SGHT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Sight Sciences, Inc. (SGHT) Could Rally 121%: Here's is How to Trade

Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Sight Sciences, Inc. (SGHT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Bears are Losing Control Over Sight Sciences, Inc. (SGHT), Here's Why It's a 'Buy' Now

MENLO PARK, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced the appointment of Tamara Fountain, M.D. to its Board of Directors, effective July 15, 2022. As part of her duties, Dr. Fountain has joined Sight Sciences' Nominating and Corporate Governance Committee.

Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors

The average of price targets set by Wall Street analysts indicates a potential upside of 199.7% in Sight Sciences, Inc. (SGHT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 200% Upside in Sight Sciences, Inc. (SGHT): Can the Stock Really Move This High?

Sight Sciences, Inc (NASDAQ:SGHT ) Q1 2022 Results Conference Call May 10, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Jesse Selnick - Chief Financial Officer Shawn O'Neil - Chief Commercial Officer Conference Call Participants Cecilia Furlong - Morgan Stanley Andrew Brackmann - William Blair Adam Butler - Piper Sandler Joanne Wuensch - Citi Operator Ladies and gentlemen, thank you for standing by, and welcome to the Sight Sciences First Quarter 2022 Earnings Results Call. At this time, all participants are in a listen-only mode.

Sight Sciences, Inc (SGHT) CEO Paul Badawi on Q1 2022 Results - Earnings Call Transcript

MENLO PARK, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced plans to participate in the upcoming Bank of America Healthcare Conference.

Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference

MENLO PARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced that data from clinical studies of the OMNI® Surgical System will be presented at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. Additionally, the Company is sponsoring a minimally invasive glaucoma surgery (MIGS) education symposium. The conference will take place April 22-26, 2022 at the Walter E. Washington Convention Center in Washington, D.C.

Sight Sciences Announces Multiple Presentations and Event at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting

MENLO PARK, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced it will report financial results for the quarter ended March 31, 2022, after the market close on Tuesday, May 10, 2022. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Sight Sciences to Report First Quarter 2022 Financial Results on May 10, 2022

Sight Sciences, Inc. (SGHT) CEO Paul Badawi on Q4 2021 Results - Earnings Call Transcript

News for Sight Sciences Stock (SGHT)